1. Home
  2. MAGN vs DBVT Comparison

MAGN vs DBVT Comparison

Compare MAGN & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Magnera Corporation

MAGN

Magnera Corporation

HOLD

Current Price

$15.15

Market Cap

536.8M

ML Signal

HOLD

DBVT

DBV Technologies S.A.

HOLD

Current Price

$19.23

Market Cap

769.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAGN
DBVT
Founded
1864
2002
Country
United States
France
Employees
N/A
N/A
Industry
Paper
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
536.8M
769.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MAGN
DBVT
Price
$15.15
$19.23
Analyst Decision
Buy
Buy
Analyst Count
1
7
Target Price
$16.00
$31.75
AVG Volume (30 Days)
722.4K
742.3K
Earning Date
02-05-2026
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,204,000,000.00
$5,502,000.00
Revenue This Year
$5.74
$1,768.71
Revenue Next Year
$2.51
$1,028.88
P/E Ratio
N/A
N/A
Revenue Growth
46.50
N/A
52 Week Low
$7.82
$2.99
52 Week High
$23.19
$26.19

Technical Indicators

Market Signals
Indicator
MAGN
DBVT
Relative Strength Index (RSI) 69.42 56.43
Support Level $14.52 $18.46
Resistance Level $15.52 $19.90
Average True Range (ATR) 0.49 1.58
MACD -0.12 -0.13
Stochastic Oscillator 80.26 19.17

Price Performance

Historical Comparison
MAGN
DBVT

About MAGN Magnera Corporation

Magnera Corp is a supplier of a diverse portfolio of specialty materials comprised of organic and synthetic raw ingredients. The company markets its own products predominantly into stable, consumer-oriented end markets, including wipes, healthcare, adult incontinence, apparel, baby, feminine care, air filtration, and food and beverage, for disposable and durable applications. It also provides technical solutions in infrastructure markets. The company's operations are organized into two operating and reportable segments: Americas and Rest of World. It derives the majority of its revenue from the Americas, which manufactures products and components of personal care, including medical garments, wipes, dryer sheets, filtration, baby diapers and adult incontinence.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: